Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. | The Motley Fool
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.

Source: The Motley Fool
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.